 |
|
|
| |
In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile
|
| |
| |
Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
Rong Liu*, Rong (Stephanie) Kong, Paul Mann, Paul Ingravallo, Ying Zhai, Ellen Xia, Peter Meinke, David Olsen, Steve Ludmerer, Joseph Kozlowski, Craig Coburn. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
